GCG and chronic kidney disease: In the absence of RCT directly comparing to nonsteroidal and selective mineralocorticoid receptor antagonists, SGLT2i and GLP-1 RA, this network meta-analysis evaluated the relative efficacy of three drugs on cardiovascular and renal outcomes in patients with T2DM and CKD.